Skip to main content
SpringerLink
Log in

The SEAS Trial

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

The pathobiology of aortic stenosis (AS) now is recognized to have many similiarities to that of atherosclerosis, a disease in which lipid lowering therapy with statin drugs has been successful. Accordingly statins have been used to attempt to retard the progression of AS with variable success. The SEAS trial compared the effects of the combination of simvastatin and ezetimibe to placebo in retarding the progression of aortic stenosis (AS) and was the largest randomized trial of such therapies. One thousand eight hundred seventy three patients with moderate AS were included. The group receiving the drugs had a large reduction in LDL cholesterol and a reduction in coronary events. However drug therapy had no effect on the progression of AS. Conclusion. While AS has many similarities to atherosclerosis, lipid lowering therapy does not affect progression of moderate to severe AS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bonow R, Carabello BA, Chatterjee K, et al.: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Circulation 2006, 114:e84–e231.

    Article  PubMed  Google Scholar 

  2. Rossebo AB, Pederson TR, Boman K, et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. SEAS Investigators. N Engl J Med 2008, 359:1343–1356.

    Article  PubMed  Google Scholar 

  3. Otto CM, Kuusisto J, Reichenback DD, et al.: Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1993, 90:844–853.

    Google Scholar 

  4. Otto CM, Lind BK, Kitzman DW, et al.: Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999, 341:142–147.

    Article  CAS  PubMed  Google Scholar 

  5. Chandra HR, Goldstein JA, Choudhary N, et al.: Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol 2004, 43:169–175.

    Article  PubMed  Google Scholar 

  6. Stewart BF, Siscovick D, Lind BK, et al.: Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol 1997, 29:630–634.

    Article  CAS  PubMed  Google Scholar 

  7. Chui MC, Newby DE, Panarelli M, et al.: Association between calcific aortic stenosis and hypercholesterolemia: is there a need for a randomized controlled trial of cholesterol-lowering therapy? Clin Cardiol 2001, 24:52–55.

    Article  CAS  PubMed  Google Scholar 

  8. Aronow WS, Ahn C, Kronzon I, Goldman ME: Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001, 88:693–695.

    Article  CAS  PubMed  Google Scholar 

  9. Pohle K, Maffert R, Ropers D, et al.: Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular factors. Circulation 2001, 104:1927–1932.

    Article  CAS  PubMed  Google Scholar 

  10. Novaro GM, Tiong IY, Pearce GL, et al.: Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001, 104:2205–2209.

    Article  CAS  PubMed  Google Scholar 

  11. Moura LM, Ramos SF, Zamorano JL, et al.: Rosuvastatin affecting aortic valve endothelium to slow progression of aortic stenosis. J Am Coll Cardiol 2007, 49:554–561.

    Article  CAS  PubMed  Google Scholar 

  12. Cowell SJ, Newby DE, Prescott RJ, et al.: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005, 352:2389–2397.

    Article  CAS  PubMed  Google Scholar 

  13. Toutouzas K, Drakopoulou M, Synetos A, et al.: In vivo aortic valve thermal heterogeneity in patients with non-rheumatic aortic valve stenosis: first in vivo experience in humans. J Am Coll Cardiol 2008, 52:758–763.

    Article  PubMed  Google Scholar 

  14. Rajamannan NM, Subramaniam M, Stock SR, et al.: Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005, 91:806–810.

    Article  CAS  PubMed  Google Scholar 

  15. Garg V, Muth AN, Ransom JF, et al.: Mutations in NOTCH1 cause aortic valve disease. Nature 2005, 437:270–274.

    Article  CAS  PubMed  Google Scholar 

  16. Goldbarg SH, Elmariah S, Miller MA, Fuster V: Insights into degenerative aortic valve disease. J Am Coll Cardiol 2007, 50:1205–1213.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflict of interest relevant to this article was reported.

Author information

Authors and Affiliations

  1. Veterans Affairs Medical Center, Medical Service (111), 2002 Holcombe Boulevard, Houston, TX, 77030, USA

    Blase A. Carabello

Authors
  1. Blase A. Carabello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Blase A. Carabello.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carabello, B.A. The SEAS Trial. Curr Cardiol Rep 12, 122–124 (2010). https://doi.org/10.1007/s11886-010-0094-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-010-0094-9

Keywords

Search

Navigation